Dear all,
Now in its tenth year, Cambridge Healthtech Institute is accepting
registrations for its upcoming SBDD meeting:
Structure-Based Drug Design:
Multidisciplinary Innovations and Structural Insights to Enhance Drug
Discovery
June 23-25, 2010
Royal Sonesta Hotel - Cambridge, Mass.
www.healthtech.com/SBD
Hear from thought-leaders including:
Structure-Based Design of AP24534, a pan-BCR-ABL Inhibitor Overriding
the T315I Gatekeeper Mutation
David Dalgarno, Ph.D., Vice President, Research Technologies, ARIAD
Pharmaceuticals, Inc.
Implementation of Protein Flexibility and Water Molecules in Docking
and Scoring Methods
Nicolas Moitessier, Ph.D., Professor, Chemistry, McGill University
The Impact of Recent X-Ray Structure Determinations on Structure-Based
Drug Design for GPCRs and other CNS Targets
Sid Topiol, Ph.D., Head of US Computational Chemistry and Structural
Investigations, Chemistry, Lundbeck Research, USA
Co-Presentation: Achieving Remarkable Potency and Selectivity Against
HCV Protease by Irreversible Covalent Inhibition Using Structure-Based
Drug Design
Deqiang Niu, Ph.D., Principal Scientist/Project Leader, Medicinal
Chemistry, Avila Therapeutics
Juswinder Singh, Ph.D., Co-Founder/Chief Scientific Officer, Avila
Therapeutics
Coupling the GPCR Structural Determination Process with Discovery and
Optimization of Small Molecule Ligands
Michael Hanson, Ph.D., Associate Director, Structural Biology,
Receptos, Inc.
Using Semi-Rational Design and Protein Folding to Engineer Highly
Specific Protein-Protein Interactions for Therapeutic Intervention
Jody Mason, Ph.D., Lecturer, Biological Sciences, University of Essex
Register by March 26th and Save up to $350
www.healthtech.com/SBD
For questions or to register by phone, call 781-972-5400 or email
jprudhomme from healthtech.com
